Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Interest Received: $310M in FY2025, down 36.6% from a year earlier.
Latest, FY2025
310
Period ended Dec 31, 2025
Change on a year earlier
-36.6%
489 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Interest received | 310 | 489”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Interest Received ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 310 | -36.6% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 489 | -24.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 645 | +156.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 252 | +1,838.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 13 | -72.3% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 47 | -78.0% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | 214 | -11.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 241 | +148.5% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 97 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Cite this data
StockData. (2026). Novartis Interest Received ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-cf-interest-rcvd
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.